Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML

Next Previous
Search
Trial Profile

A Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Danvatirsen (Primary) ; Venetoclax (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Dec 2024 Trial design presented at the 66th American Society of Hematology Annual Meeting and Exposition.
    • 04 Dec 2024 According to a Flamingo Therapeutics media release, company announced that an abstract from this Phase 1 Study has been selected for presentation at the 66th Annual ASH Annual Meeting and Exposition, being held in San Diego, CA on Monday, December 9, 2024.
    • 16 May 2024 According to a Flamingo Therapeutics media release, this Investigator initiated trial is being conducted by leading researchers at Montifore Einstein Comprehensive Cancer Center (MECCC; New York, USA) and MD Anderson Cancer Center (MDACC; Houston, USA). The trial is being funded by a multi-year grant awarded by the US FDA Office of Orphan Products Development (OOPD) to MECCC.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top